The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T.
Katayama R, et al. Among authors: tominaga y.
Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z.
Nat Commun. 2019.
PMID: 31399568
Free PMC article.